Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design
This study, designed to emulate a randomized trial, suggests that, in French patients with chronic myeloid leukemia treated with BCR-ABL TKIs, dasatinib use is associated with a higher risk of PAH compared with imatinib, while bosutinib and ponatinib exposure may aggravate or trigger a recurrence of PAH in patients with preexisting dasatinib exposure. Whether bosutinib and ponatinib could induce PAH without preexposure to dasatinib remains to be explored.
Authors
- Clément Jambon-Barbara (ORCID: https://orcid.org/0000-0002-6619-4130)
- Charles Khouri (ORCID: https://orcid.org/0000-0002-8427-8573)
- Alex Hlavaty (ORCID: https://orcid.org/0009-0002-8483-5023)
- Jean‐Luc Cracowski (ORCID: https://orcid.org/0000-0003-0787-1469)
- David Montani
- Sophie Dell’Aniello
- Samy Suissa
- Marc Humbert
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- CEA Paris-Saclay - Etablissement de Saclay (FR)
- McGill University Health Centre (CA)
- Jewish General Hospital (CA)
- Hôpital Marie Lannelongue (FR)
- Bicêtre Hospital (FR)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Circulation
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1161/circulationaha.125.077764
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00